Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
about
Classic tumor markers in gastric cancer. Current standards and limitationsTranslational progress on tumor biomarkersThe combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancerDetection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer.Clinicopathological features and prognosis of gastric cancer in young patientsLong non-coding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancerA clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.CdSe/ZnS Quantum Dot-Labeled Lateral Flow Strips for Rapid and Quantitative Detection of Gastric Cancer Carbohydrate Antigen 72-4.Elevated Preoperative Serum Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) Ratio Is Associated with Better Prognosis in Patients Undergoing Curative Treatment for Gastric Adenocarcinoma.Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.Combined preoperative concentrations of CEA, CA 19-9, and 72-4 for predicting outcomes in patients with gastric cancer after curative resection.NONHSAT076754 aids ultrasonography in predicting lymph node metastasis and promotes migration and invasion of papillary thyroid cancer cells.Tumour-associated antigens and their anti-cancer applications.Prognostic value of systemic immune-inflammation index in patients with gastric cancer.Expression and Clinical Significance of ILF2 in Gastric Cancer.Pre-operative to post-operative serum carcinoembryonic antigen ratio is a prognostic indicator in colorectal cancer.Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer.Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma.Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.A novel classifier based on three preoperative tumor markers predicting the cancer-specific survival of gastric cancer (CEA, CA19-9 and CA72-4).Stage Association of Preoperative Serum Carcinoembryonic Antigen with Gastric Adenocarcinoma in Iranian PatientsClinicopathological features and prognosis in elderly gastric cancer patients: a retrospective cohort study.Associations between CA19-9 and CA125 levels and human epidermal growth factor receptor 2 overexpression in patients with gastric cancer.UEG Week 2015 Poster Presentations
P2860
Q26777296-6327562D-AF07-458E-A484-B139CCAF6C03Q26777676-2ED6436E-4275-498E-A06F-D64C31912421Q33591586-5C379DF6-2560-4E38-A1D1-A1C7C2EB8628Q33607505-13001A4A-A4F2-4319-BA77-11C96E78F011Q35764908-0F930BC4-8200-4716-A099-C0C2E36450A1Q36078244-69452C54-30CC-486E-8EF6-F85B0C9580B1Q36375276-C5F2A4F2-1E98-4A0F-BE36-A9DA8F043F47Q36631514-9A63D784-3C81-454B-BD5A-B6D582FBBF9AQ36678385-75D23B47-332B-47B7-8416-6E5EF92E2DD0Q37050708-89DE618C-F710-4809-BCB8-98140E885E63Q37376572-F6C3FDE8-6F15-4D94-94BB-66C54B77345CQ37376581-2D531715-8975-4ECE-B7B1-216D658B91DFQ37709272-230215B6-AF51-4670-AE9A-0DEEBDEE3BB1Q38725552-665F1BA8-44A7-46F3-8ECF-1BA206A0BB34Q41152020-661EEF99-B075-40D2-ABF2-38C45CFAFCBEQ41376426-A80AE17F-2EE2-4999-8B1E-6E6E2CC3BC26Q41551062-16B2AA84-4FC5-4222-B736-CD1A0625FDD2Q41612982-14DB3B1E-A07D-4A84-BCFE-549F8C2C29EBQ47240512-665E1A9D-8E3D-4C2E-9519-B573AF36D5A3Q48219339-E86395E5-AFA2-4114-8A82-977354463011Q49219389-74519ADC-E5C7-4445-A757-D5C94C6CFA17Q50052974-B5C4B010-61C5-4F01-9FC9-39ED24C98C4FQ50087853-08962FC9-5267-456D-96D2-DB93774F19E1Q55096294-2B43A63B-E9F9-4C4F-926F-EC8BF7A08BBFQ55356265-6AD5D4EE-8080-4E14-A621-6D1150EB7AFFQ56934656-D740AACA-88D9-4977-B203-3F853BA4E72B
P2860
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical evaluation of CEA, CA ...... with neoadjuvant chemotherapy.
@ast
Clinical evaluation of CEA, CA ...... with neoadjuvant chemotherapy.
@en
type
label
Clinical evaluation of CEA, CA ...... with neoadjuvant chemotherapy.
@ast
Clinical evaluation of CEA, CA ...... with neoadjuvant chemotherapy.
@en
prefLabel
Clinical evaluation of CEA, CA ...... with neoadjuvant chemotherapy.
@ast
Clinical evaluation of CEA, CA ...... with neoadjuvant chemotherapy.
@en
P2860
P356
P1476
Clinical evaluation of CEA, CA ...... with neoadjuvant chemotherapy.
@en
P2093
Nengwei Zhang
P2860
P2888
P356
10.1186/1477-7819-12-397
P50
P577
2014-12-29T00:00:00Z
P5875
P6179
1023778624